View Cart (0 items)

Articles Tagged with ''pharmaceutical industry''

Shire agrees to acquire NPS Pharma for $5.2 billion

British pharmaceutical company Shire plc has agreed to acquire U.S.-based NPS Pharma for $5.2 billion, strengthening its capabilities in treating rare diseases and gastrointestinal disorders.
Read More

Pfizer boosts vaccine portfolio with Redvax acquisition

Pfizer Inc. has acquired a controlling interest in Switzerland's Redvax GmbH, the company announced on Monday.
Read More

Pharmaceutical excipients market worth $6.1 billion this year

The market for pharmaceutical excipients has seen strong growth over the past few years and is forecast to expand at a compound annual growth rate (CAGR) of 6.7 percent from 2014 to 2019.
Read More

BioMarin to acquire DMD drug developer Prosensa

Biopharmaceuticals company BioMarin Pharmaceutical Inc. revealed on Monday that it has agreed to acquire Prosensa Holding N.V., a drug developer with a focus on rare neuromuscular and neurodegenerative disorders.
Read More

Merck agrees to $8.4 billion deal for antibiotics developer Cubist

Healthcare giant Merck & Co., Inc. is to acquire antibiotics specialist Cubist Pharmaceuticals, Inc. for $8.4 billion, the company announced on Monday.
Read More

Japan's Otsuka to acquire Avanir Pharmaceuticals for $3.5 billion

The Japanese company said on Tuesday that this acquisition would strengthen its business in the area of neurological conditions.
Read More

Rise in asthma, COPD cases driving pulmonary drug delivery systems market

The global market revenue of pulmonary drug delivery systems is expected to increase at a compound annual growth rate (CAGR) of 8.9 percent over the period 2014-2019.
Read More

Healthy growth predicted for empty capsules market

Capsules are widely considered an efficient method of taking medication and health supplements, and their use is set to grow in the coming years.
Read More

Bristol-Myers Squibb to build new biologics manufacturing plant in Ireland

The new manufacturing facility will produce multiple therapies for the biopharmaceutical company's growing portfolio of approved and investigational biologic medicines in therapeutic areas including oncology, virology and immunoscience.
Read More

Allergan enters acquisition deal with Actavis

Botox maker Allergan, Inc. will be acquired by Actavis plc for $66 billion after fending off a hostile takeover bid by activist investor William Ackman and Valeant Pharmaceuticals International Inc.
Read More